Compugen Stock Forecast, Price & News

-0.07 (-1.09 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume892,104 shs
Average Volume1.20 million shs
Market Capitalization$436.52 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

Compugen logo

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.71 out of 5 stars

Medical Sector

778th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

113th out of 213 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Compugen (NASDAQ:CGEN) Frequently Asked Questions

Is Compugen a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Compugen stock.
View analyst ratings for Compugen
or view top-rated stocks.

What stocks does MarketBeat like better than Compugen?

Wall Street analysts have given Compugen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Compugen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for Compugen

How can I listen to Compugen's earnings call?

Compugen will be holding an earnings conference call on Wednesday, July 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) posted its quarterly earnings results on Thursday, May, 13th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. During the same quarter in the prior year, the firm posted ($0.10) EPS.
View Compugen's earnings history

How has Compugen's stock price been impacted by Coronavirus (COVID-19)?

Compugen's stock was trading at $11.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CGEN stock has decreased by 46.1% and is now trading at $6.38.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CGEN?

3 equities research analysts have issued twelve-month price objectives for Compugen's shares. Their forecasts range from $16.00 to $20.00. On average, they expect Compugen's share price to reach $18.33 in the next twelve months. This suggests a possible upside of 187.4% from the stock's current price.
View analysts' price targets for Compugen
or view top-rated stocks among Wall Street analysts.

Who are Compugen's key executives?

Compugen's management team includes the following people:
  • Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 54, Pay $989.87k)
  • Mr. Ari Krashin, Chief Financial & Operating Officer (Age 48, Pay $545.18k)
  • Dr. Oliver Froescheis Ph.D., Sr. VP of Corp. & Bus. Devel. (Age 55, Pay $453.25k)
  • Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 53, Pay $339.19k)
  • Dr. Henry Adewoye M.D., Sr. VP & Chief Medical Officer (Age 56, Pay $589.09k)
  • Ms. Donna Gershowitz, Gen. Counsel (Age 57)
  • Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 52)
  • Ms. Dorit Amitay, VP of HR (Age 53)
  • Dr. Yaron Turpaz M.B.A., Ph.D., MBA, Sr. VP & Sr. Advisor of Computational Discovery (Age 50)
  • Rivka Schwartz, VP Research and Discovery

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen CEO Anat Cohen-Dayag on Anat Cohen-Dayag has an approval rating of 100% among Compugen's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Compugen's key competitors?

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (0.95%).

Which major investors are buying Compugen stock?

CGEN stock was bought by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $6.38.

How much money does Compugen make?

Compugen has a market capitalization of $436.52 million and generates $2 million in revenue each year. The biotechnology company earns $-29,700,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Compugen have?

Compugen employs 68 workers across the globe.

What is Compugen's official website?

The official website for Compugen is

Where are Compugen's headquarters?

Compugen is headquartered at Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.